Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

被引：5
|
作者：
Hussain, Syed A.
Maroto, Pablo
Climent, Miguel Angel
Bianchini, Diletta
Jones, Robert Hugh
Lin, Chia-Chi
Wang, Shian-Shiang
Dean, Emma
Crossley, Kate
Schlieker, Laura
Bogenrieder, Thomas
De Bono, Johann S.
机构：
[1] Univ Sheffield, Acad Unit Oncol, Dept Oncol & Metab, Sheffield, S Yorkshire, England
[2] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[3] Inst Valenciano Oncol, Valencia, Spain
[4] Inst Canc Res, London, England
[5] Royal Marsden, London, England
[6] Velindre Canc Ctr, Cardiff, S Glam, Wales
[7] Cardiff Univ, Cardiff, S Glam, Wales
[8] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[9] Taichung Vet Gen Hosp, Taichung, Taiwan
[10] Christie NHS Fdn Trust, Manchester, Lancs, England
[11] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[12] Boehringer Ingelheim Pharma Gmbh & Co KG, Staburo Gmbh & Co KG, Munich, Germany
[13] Boehringer Ingelheim RCV, Vienna, Austria
[14] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Dept Urol, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5030
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
    Sridhar, Srikala S.
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Rodriguez, Jose Maria M. Piulats
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921
    Petrylak, Daniel Peter
    Shore, Neal D.
    Bennamoun, Mostefa
    Ratta, Raffaele
    Piulats, Josep M.
    Li, Ben
    Schloss, Charles
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [23] BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone plus olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.
    Hussain, Maha H. A.
    Kocherginsky, Masha
    Agarwal, Neeraj
    Zhang, Jingsong
    Adra, Nabil
    Paller, Channing Judith
    Picus, Joel
    Reichert, Zachery R.
    Szmulewitz, Russell Zelig
    Tagawa, Scott T.
    Whang, Young E.
    Dreicer, Robert
    Kuzel, Timothy
    Bazzi, Latifa
    Gerke, Travis A.
    Daignault-Newton, Stephanie
    Chinnaiyan, Arul
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
    Caffo, Orazio
    Palesandro, Erica
    Nole, Franco
    Gasparro, Donatello
    Mucciarini, Claudia
    Aieta, Michele
    Zagonel, Vittorina
    Iacovelli, Roberto
    De Giorgi, Ugo
    Rossetti, Sabrina
    Fratino, Lucia
    Sacco, Cosimo
    Nicodemo, Maurizio
    Giordano, Monica
    Sartori, Donata
    Scapoli, Daniela
    Verri, Elena
    Kinspergher, Stefania
    Pappagallo, Giovanni L.
    Aglietta, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [25] Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial
    Khalaf, Daniel J.
    Sunderland, Katherine
    Eigl, Bernhard J.
    Kollmannsberger, Christian K.
    Ivanov, Nikita
    Finch, Daygen L.
    Oja, Conrad
    Vergidis, Joanna
    Zulfiqar, Muhammad
    Gleave, Martin E.
    Chi, Kim N.
    EUROPEAN UROLOGY, 2019, 75 (06) : 940 - 947
  • [26] A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
    Climent, Miguel A.
    Font, Albert
    Duran, Ignacio
    Puente, Javier
    Mendez-Vidal, Maria Jose
    Isabel Saez, Maria
    Lobera, Carmen Santander
    Arranz Arija, Jose Angel
    Gonzalez-Del-Alba, Aranzazu
    Sanchez-Hernandez, Alfredo
    Juan Fita, Maria Jose
    Esteban, Emilio
    Alonso-Gordoa, Teresa
    Mellado Gonzalez, Begona
    Maroto, Pablo
    Lazaro-Quintela, Martin
    Cassinello-Espinosa, Javier
    Perez-Valderrama, Begona
    Garcias, Carmen
    Castellano, Daniel
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : 110 - 119
  • [27] Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Eigl, Bernhard J.
    Eliasziw, Misha
    North, Scott A.
    Trudeau, Marc G.
    Winquist, Eric
    Chi, Kim N.
    Ruether, Joseph D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [28] Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Sternberg, C. N.
    Bracarda, S.
    de Bono, J. S.
    Sweeney, C.
    Chi, K. N.
    Olmos, D.
    Sandhu, S. K.
    Massard, C.
    Garcia, J.
    Schenkel, F.
    Chen, G.
    Harris, A.
    Hinton, H.
    Matsubara, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S635 - S636
  • [29] Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
    Romano, E.
    Sridhar, S. S.
    Kolinsky, M. P.
    Gravis, G.
    Mourey, L.
    Piulats, J. M.
    Berry, W. R.
    Gurney, H.
    Retz, M.
    Appleman, L. J.
    Boegemann, M.
    de Bono, J. S.
    Joshua, A. M.
    Emmenegger, U.
    Conter, H. J.
    Laguerre, B.
    Wu, H.
    Qiu, P.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S512 - S513
  • [30] Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
    Conter, Henry Jacob
    Shore, Neal D.
    Berry, William R.
    Fong, Peter C. C.
    Rodriguez, Jose Maria M. Piulats
    Appleman, Leonard Joseph
    Todenhoefer, Tilman
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    De Bono, Johann S.
    Kam, Audrey E.
    Emmenegger, Urban
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345